Rakovina Therapeutics Inc(RKV-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.140
Day High0.150
Open:0.140
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update
Newsfile
Upcoming Meeting Dates - May 25, 2026
Newsfile
Upcoming Meeting Dates - May 4, 2026
GlobeNewswire
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
GlobeNewswire
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
GlobeNewswire
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum
GlobeNewswire
Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
GlobeNewswire
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
GlobeNewswire
Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
GlobeNewswire
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
GlobeNewswire
Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
GlobeNewswire
Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
GlobeNewswire
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
GlobeNewswire
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
GlobeNewswire
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
GlobeNewswire
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
GlobeNewswire
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
GlobeNewswire
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
GlobeNewswire
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

Profile

Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.